Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2011

01-04-2011 | Research Article

Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure

Authors: Yasukazu Sagawa, Atsuya Fujitoh, Hirotaka Nishi, Hiroe Ito, Tamaki Yudate, Keiichi Isaka

Published in: Tumor Biology | Issue 2/2011

Login to get access

Abstract

Using the endometrial cancer cell line EI established in our department, we attempted to establish cisplatin (CDDP)-resistant cell lines by incremental exposure and high concentration exposure methods. Three CDDP-resistant cell lines were isolated, which could be distinguished by morphological differences.
1.
Upon acquiring CDDP resistance, the cells tended to become small and grow in a floating state. This tendency was especially marked when using incremental exposure method. Using the incremental exposure method, a cell line obtained by isolating and culturing only adherent cells was designated EICR-Ia, and a cell line established by culturing only floating cells was designated EICR-If. A cell line obtained by the high concentration exposure method was designated EICR-II.
 
2.
Upon acquiring CDDP resistance, tumor markers such as TPA and LDH increased, while proliferative capability of the cells was lowered.
 
3.
The invasion capability was diminished in EICR-If cells, but was increased in EICR-Ia and EICR-II cells.
 
4.
Following exposure to CDDP, the intracellular platinum concentrations were markedly elevated in EI and EICR-If cells, whereas the increase was mild in EICR-Ia and EICR-II cells and the concentration was lower than that in parent EI cells.
 
5.
Studies of drug resistance gene expression revealed increased expression of MDR1, GSTπ, and Topo-II in EICR-If cells; increased expression of GSTπ in EICR-II cells; but no expression of any of the genes in EICR-Ia cells.
 
6.
Analyses of cancer- and apoptosis-related genes showed increased expressions of Bcl-2, c-Myc, p53, and ICE in EICR-If cells.
 
7.
Upon acquiring CDDP resistance, sensitivity to mitomycin and adriamycin decreased, but sensitivity to etoposide and 5-fluorouracil increased.
 
The findings indicate that the mechanisms of CDDP resistance are different in the three cell lines.
Literature
1.
Tominaga S et al. Cancer mortality and morbidity statistics. Tokyo: Japan Scientific Societies; 1994.
2.
Rosenberg B, VanCamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–9.CrossRefPubMed
3.
Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21:107–13.PubMed
4.
Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD. Phase II trial of cisplatin as secondline chemotherapy in patients with advanced or recurrent endometrial carcinoma. A gynecologic oncology group study. Am J Clin Oncol. 1984;7:253–6.CrossRefPubMed
5.
Deppe G, Cohen CJ, Bruckner HW. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. Gynecol Oncol. 1980;10:51–4.CrossRefPubMed
6.
Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol. 1982;59:225–8.PubMed
7.
Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ, et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol. 1991;40:264–7.CrossRefPubMed
8.
Barrete RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. Am J Clin Oncol. 1993;16:494–6.CrossRef
9.
Belliveau JF, Posner MR, Ferrari L, Crabtree GW, Cummings FJ, Wiemann MC, et al. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treat Rep. 1986;70:1215–7.PubMed
10.
Yudate T, Isaka K, Okabe K, Takayama M. Establishment and characterization of the new cell line (EI) from a human endometrial adenocarcinoma. (in Japanese with English abstract) HUMAN CELL. 1995;8(1):43–7.PubMed
11.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinease hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152–62.CrossRefPubMed
12.
Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. J Biol Chem. 1987;262:505–8.PubMed
13.
Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004–8.CrossRefPubMed
14.
Gottesman MM, Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 1988;263:12163–6.PubMed
15.
Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1998;948:87–128.
16.
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst. 1989;81:116–24.CrossRefPubMed
17.
Cole SP, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–4.CrossRefPubMed
18.
Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance protein, MRP. Eur J Cancer. 1996;32:945–57.CrossRef
19.
Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992;89:3070–4.CrossRefPubMed
20.
Lai GM, Moscow JA, Alvarez MJ, Fojo AT, Bates SE. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer. 1991;49:688–95.CrossRefPubMed
21.
Xu BH, Gupta V, Singh SH. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. Arch Biochem Biophys. 1994;308:164–70.CrossRefPubMed
22.
Sriram R, Ali-Osman F, Livingston R, et al. Modulation of topoisomerase (Topo) II on the kinetics of formation and repair of cis-platinum (cis-DDP) in human tumor cells sensitive and resistant to cis-DDP. Proc Am Assoc Cancer Res. 1990;31:335.
23.
Dejong S, Zijlstra JG, Mulder MH, Devries EG. Lack of cross-resistance to fustriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol. 1991;28:461–4.CrossRef
24.
Waud WR, Harrison SDJ, Gilbert KS, Laster Jr WR, Griswold Jr DP. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol. 1991;27:456–63.CrossRefPubMed
25.
Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem. 1983;258:15365–70.PubMed
26.
Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845–53.PubMed
27.
Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ. Apoptosis and metastasis: increased resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett. 1997;115:185–93.CrossRefPubMed
28.
29.
Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nat Genet. 1997;16:358–63.CrossRefPubMed
30.
Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes. Nature. 1992;356:768–74.CrossRefPubMed
31.
Lowe SW, Bodis S, MaClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807–10.CrossRefPubMed
Metadata
Title
Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure
Authors
Yasukazu Sagawa
Atsuya Fujitoh
Hirotaka Nishi
Hiroe Ito
Tamaki Yudate
Keiichi Isaka
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0133-6

Other articles of this Issue 2/2011

Tumor Biology 2/2011 Go to the issue

Review

Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family

Research Article

Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate

Research Article

Prognostic significance of HE4 expression in pulmonary adenocarcinoma

Research Article

Oral squamous cell carcinoma versus oral verrucous carcinoma: an approach to cellular proliferation and negative relation to human papillomavirus (HPV)

Research Article

MMP-7 as a prognostic marker in colorectal cancer

Research Article

Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits